Max Heiduk
Overview
Explore the profile of Max Heiduk including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
154
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wong F, Merker S, Bauer L, Han Y, Le V, Wenzel C, et al.
Br J Cancer
. 2025 Jan;
132(4):326-339.
PMID: 39863771
Background: Pancreatic ductal adenocarcinoma (PDAC) exhibits a high frequency of neural invasion (NI). Schwann cells (SCs) have been shown to be reprogrammed to facilitate cancer cell migration and invasion into...
2.
Digomann D, Heiduk M, Reiche C, Gluck J, Kahlert C, Mirtschink P, et al.
NPJ Precis Oncol
. 2023 Oct;
7(1):104.
PMID: 37838778
Pancreatic ductal adenocarcinoma (PDAC) responds poorly to systemic treatment, including new immunotherapeutic approaches. Biomarkers are urgently needed for early disease detection, patient stratification for treatment, and response prediction. The role...
3.
Digomann D, Strack J, Heiduk M, Plesca I, Rupp L, Reiche C, et al.
Cancers (Basel)
. 2023 May;
15(8).
PMID: 37190254
Immunotherapy has shown promising results in multiple solid tumors and hematological malignancies. However, pancreatic ductal adenocarcinoma (PDAC) has been largely refractory to current clinical immunotherapies. The V-domain Ig suppressor of...
4.
Heiduk M, Klimova A, Reiche C, Digomann D, Beer C, Aust D, et al.
Clin Cancer Res
. 2023 May;
29(14):2638-2650.
PMID: 37140899
Purpose: Immunotherapy has led to a fundamental shift in the treatment of several cancers. However, its efficacy in pancreatic ductal adenocarcinoma (PDAC) is limited. Understanding the expression of inhibitory immune...
5.
Heiduk M, Plesca I, Gluck J, Muller L, Digomann D, Reiche C, et al.
JCI Insight
. 2022 Dec;
7(22).
PMID: 36509285
BACKGROUNDPancreatic ductal adenocarcinoma (PDAC) has a dismal prognosis. At diagnosis, only 20% of patients with PDAC are eligible for primary resection. Neoadjuvant chemotherapy can enable surgical resection in 30%-40% of...
6.
Plesca I, Benesova I, Beer C, Sommer U, Muller L, Wehner R, et al.
Cancers (Basel)
. 2022 Mar;
14(5).
PMID: 35267524
Dendritic cells (DCs) play a key role in the orchestration of antitumor immunity. Activated DCs efficiently enhance antitumor effects mediated by natural killer cells and T lymphocytes. Conversely, tolerogenic DCs...
7.
Seifert L, Plesca I, Muller L, Sommer U, Heiduk M, von Renesse J, et al.
Cancers (Basel)
. 2021 Apr;
13(6).
PMID: 33803936
T cells are the predominant immune cell population in the pancreatic tumor microenvironment. High CD8 and Th1-polarized CD4 T cell infiltration is associated with prolonged survival in human pancreatic ductal...
8.
Seifert A, Eymer A, Heiduk M, Wehner R, Tunger A, von Renesse J, et al.
Cancers (Basel)
. 2020 Sep;
12(10).
PMID: 32987956
Pancreatic ductal adenocarcinoma (PDAC) is characterized by a mostly immunosuppressive microenvironment. Tumor-draining lymph nodes (TDLN) are a major site for priming of tumor-reactive T cells and also tumor metastasis. However,...
9.
Seifert A, List J, Heiduk M, Decker R, von Renesse J, Meinecke A, et al.
J Cancer Res Clin Oncol
. 2020 Sep;
146(12):3233-3240.
PMID: 32865617
Introduction: The immunosuppressive tumor microenvironment promotes progression of pancreatic ductal adenocarcinoma (PDAC). γδ T cells infiltrate the pancreatic tumor stroma and support tumorigenesis through αβ T cell inhibition. Pancreatic stellate...
10.
Seifert A, Reiche C, Heiduk M, Tannert A, Meinecke A, Baier S, et al.
Oncogene
. 2020 Feb;
39(15):3102-3113.
PMID: 32055023
Pancreatic ductal adenocarcinoma (PDAC) responds poorly to checkpoint blockade, such as anti-CTLA-4 and anti-PD-1. Galectin-9, a β-galactoside-binding lectin, promotes immune suppression through T-cell inhibition, and programming of tolerogenic macrophages. Of...